News

The round was led by Edmond de Rothschild Investment Partners, with participation from Biogen Idec New Ventures and Fortis Private Equity, as well as existing series B investors

The joint-venture company, StemCyte India Therapeutics, will provide stem cell therapies derived from umbilical cord blood to treat patients with certain malignant blood disorders, including leukemia, lymphoma, myeloma

The pending patent covers systemic use of the drug, PH-12, for photodynamic treatment of cancer, skin diseases, and other tissue disorders using visible light activation. Craig Dees, CEO

The company said that in addition to alomost 35 years of experience serving a global customer base, BioVectra’s FDA-approved cGMP facility was a key factor in awarding the

This round brings the total amount raised since the company’s inception to date to E27 million. The financing strengthens the company’s balance sheet and allows the progression of

Analysis of the pharmacokinetic data from this study and other bevirimat clinical studies has revealed the bevirimat target blood levels, or threshold, above which patients are likely to

Researchers at Brown Cancer Center have discovered that 3PO inhibits a key enzyme, PFKFB3, which suppresses both sugar metabolism and cell proliferation among cancer cells. In addition, 3PO

The vaccine, which was developed by Memorial Sloan-Kettering Cancer Center scientists, consists of DNA encoding a form of the tyrosinase protein. In the first stage of the trial,

The agreement terms include a license fee based on the achievement of specific regulatory milestones and a sales-based royalty arrangement once regulatory clearances are established. Planned expenditures for